Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study

Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study

OBJECTIVES: Lung cancer is the leading cause of cancer-related deaths worldwide. However, factors associated with the survival of patients with advanced non-small-cell lung cancer (NSCLC) who received only hospice care are largely unclear. In this study, we aimed to determine the prognostic factors...

Full description

Bibliographic Details
Main Authors:	Yan Lan, Shuo Zhou, Weihong Feng, Ying Qiao, Xueming Du, Fenge Li
Format:	Article
Language:	English
Published:	Elsevier España 2021-03-01
Series:	Clinics
Subjects:	Lung Cancer Hospice Care EGFR Inhibitor Overall Survival Tumor Mutation
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322021000100238&tlng=en

Similar Items

Survival Analysis of Lung Adenocarcinoma Patients with Exon 19 Del and 21 L858R Mutations Receiving EGFR-TKI Treatment
by: Stephen Johan Prasetyo, et al.
Published: (2023-05-01)

Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors
by: Hisao Imai, et al.
Published: (2019-12-01)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
by: Hyun Ae Jung, et al.
Published: (2020-10-01)

Predictive Role of EGFR Mutation Status on Postoperative Prognosis in Patients  with Resected Lung Adenocarcinomas
by: Hao BAI, et al.
Published: (2013-04-01)

Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
by: Ning Li, et al.
Published: (2022-01-01)

Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab
by: How-Wen Ko, et al.
Published: (2022-07-01)

Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing <i>EGFR</i> Mutations
by: Hisao Imai, et al.
Published: (2021-05-01)

Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies
by: Karam Khaddour, et al.
Published: (2021-06-01)

Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies
by: Alexander Hendricks, et al.
Published: (2020-02-01)

The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis
by: Liyuan Ke, et al.
Published: (2022-11-01)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
by: Shoko Sonobe Shimamura, et al.
Published: (2022-03-01)

Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma
by: Michelle Levy, et al.
Published: (2017-12-01)

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
by: Tetsuya Isaka, et al.
Published: (2022-09-01)

Metastatic lymph node burden impacts overall survival in submandibular gland cancer
by: Lei Wang, et al.
Published: (2023-11-01)

Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation
by: Jianfeng Peng, et al.
Published: (2021-09-01)

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA
by: Yan Li, et al.
Published: (2022-08-01)

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma
by: LIN Qingyue, et al.
Published: (2022-12-01)

The number of brain metastases predicts the survival of non‐small cell lung cancer patients with EGFR mutation status
by: Jun Shao, et al.
Published: (2022-09-01)

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
by: Obradovic Jasmina, et al.
Published: (2012-12-01)

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
by: Atmaca Akin, et al.
Published: (2012-11-01)

Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor
by: Tasia Amelia, et al.
Published: (2022-12-01)

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients
by: Moom R. Roosan, et al.
Published: (2021-06-01)

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, et al.
Published: (2022-01-01)

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
by: Carlos E. Bacchi, et al.
Published: (2012-01-01)

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma
by: Chan Shen, et al.
Published: (2022-04-01)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
by: Yongdong Feng, et al.
Published: (2021-05-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
by: Wu Z, et al.
Published: (2019-10-01)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
by: Bailong Liu, et al.
Published: (2021-09-01)

Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era
by: Valéry Refeno, et al.
Published: (2021-08-01)

Clinical characteristics of miliary pulmonary metastases in non‐small cell lung cancer
by: Hanmil Choi, et al.
Published: (2023-08-01)

Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer
by: Mengting Zhou, et al.
Published: (2019-11-01)

Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
by: How-Wen Ko, et al.
Published: (2022-10-01)

BLM mutation is associated with increased tumor mutation burden and improved survival after immunotherapy across multiple cancers
by: Huiping Shi, et al.
Published: (2024-01-01)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
by: Yongfeng Wu, et al.
Published: (2019-11-01)

Survival of Patients With Primary Cutaneous Melanoma (Stages 0-IIА and IIB-IIC), Depending on the Presence of the <i>BRAF</i> Mutation in the Tumor and Surgical Treatment Option
by: S. A. Yаrgunin, et al.
Published: (2024-03-01)

Rare T263P epidermal growth factor receptor extracellular domain mutation of advanced non‐small cell lung cancer in a Vietnamese male patient
by: Kien Hung Do, et al.
Published: (2023-07-01)

Epidermal Growth Factor Receptor in Pancreatic Cancer
by: Ajith K. Siriwardena, et al.
Published: (2011-03-01)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
by: Yan You, et al.
Published: (2020-03-01)

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
by: Fei Ren, et al.
Published: (2022-08-01)

Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer
by: Almasri H, et al.
Published: (2022-10-01)